Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors Meeting Abstract


Authors: Harding, J. J.; Telli, M. L.; Munster, P. N.; Le, M. H.; Molineaux, C.; Bennett, M. K.; Mittra, E.; Burris, H. A.; Clark, A. S.; Dunphy, M.; Meric-Bernstam, F.; Patel, M. R.; DeMichele, A.; Infante, J. R.
Abstract Title: Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors
Meeting Title: 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036900545
PROVIDER: wos
Notes: Meeting Abstract: 2512 -- Source: Wos
MSK Authors
  1. James Joseph Harding
    66 Harding
  2. Mark Phillip Dunphy
    48 Dunphy